+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Esperion Therapeutics Inc - logo
Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Market Insight, Epidemiology and Market Forecast -2032 - Product Thumbnail Image

Familial Hypercholesterolemia (Type II Hyperlipoproteinemia) - Market Insight, Epidemiology and Market Forecast -2032

  • Report
  • January 2022
  • 200 Pages
  • Global
From
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Coronary Artery Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Coronary Artery Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Licensing Deals in Pharmaceuticals 2019-2024 - Product Thumbnail Image

Licensing Deals in Pharmaceuticals 2019-2024

  • Report
  • March 2024
  • 1300 Pages
  • Global
From
Cholesterol Absorption Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cholesterol Absorption Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Rare Diseases Treatment Global Market Report 2024 - Product Thumbnail Image

Rare Diseases Treatment Global Market Report 2024

  • Report
  • February 2024
  • 200 Pages
  • Global
From
Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline Insight, 2024 - Product Thumbnail Image

Peroxisome Proliferator-Activated Receptor (PPAR) Agonist - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Acute Coronary Syndrome: Competitive Landscape to 2026 - Product Thumbnail Image

Acute Coronary Syndrome: Competitive Landscape to 2026

  • Report
  • June 2018
  • 49 Pages
  • Global
From
Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020 - Product Thumbnail Image

Non-Alcoholic Steatohepatitis (NASH) - Pipeline Review, H2 2020

  • Drug Pipelines
  • July 2020
  • 1101 Pages
  • Global
From
Esperion Therapeutics Inc (ESPR:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry - Product Thumbnail Image

Esperion Therapeutics Inc (ESPR:NAS): Analytics, Extensive Financial Metrics, and Benchmarks Against Averages and Top Companies Within its Industry

  • Company Profile
  • May 2023
  • 89 Pages
From
Comprehensive Report on Esperion Therapeutics Inc, including SWOT, PESTLE and Business Model Canvas - Product Thumbnail Image

Comprehensive Report on Esperion Therapeutics Inc, including SWOT, PESTLE and Business Model Canvas

  • SWOT Analysis
  • August 2023
  • 90 Pages
From
Loading Indicator